Combination studies in a number of clinical trials also support the use of HDAC inhibitors with other anti-tumour agents such as bortezomib [20], but dose limiting toxicities are frequently observed and efficacy needs to be improved. This evidence concerns the gene HDAC9 and neoplasm.